BIO-TECHNE Corp Derivative Asset
BIO-TECHNE Corp (TECH) had Derivative Asset of $2.84 million as of 2025-06-30, per its 10-K filed 2025-08-22.
Financial Statements › Balance Sheet › Assets
us-gaap:DerivativeAssets · last filed 2025-08-22
- 2025-06-30: Derivative Asset $2.84M.
- 2025-03-31: Derivative Asset $0.00.
- 2024-12-31: Derivative Asset $3.23M.
- 2024-09-30: Derivative Asset $6.67M.
| Period end | Derivative Asset |
|---|---|
| 2025-06-30 | $2.84M 10-K · filed 2025-08-22 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 |
| 2024-12-31 | $3.23M 10-Q · filed 2025-02-06 |
| 2024-09-30 | $6.67M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $9.81M 10-K · filed 2025-08-22 |
| 2024-03-31 | $12.03M 10-Q · filed 2024-05-06 |
| 2023-12-31 | $11.59M 10-Q · filed 2024-02-07 |
| 2023-09-30 | $17.49M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $16.86M 10-K · filed 2024-08-22 |
| 2022-06-30 | $11.03M 10-K · filed 2023-08-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |